Uncategorized

Partnership to supply the global marketplace with pharmaceutical API phytocannabinoid ingredients formulated with a clinically proven drug delivery system technology. The partnership will allow Geocann to have the exclusive distribution rights of Averix Bio phytocannabinoid ingredients in the rapidly evolving South American marketplace where they will offer pharmaceutical API starting materials, available as either stand-alone […]

For immediate release: Antwerp, BE (11 March, 2022) Kreglinger Europe NV (Kreglinger) today announces the execution of a Distribution and Supply Agreement with Averix Bio, LLC (“Averix Bio”), a US based, North Carolina-registered company whose office is at 3040 Black Creek Road South, Wilson, N.C. 27893, USA. With this agreement in place, Kreglinger and Averix Bio are poised to

For immediate release:   Wilson, North Carolina (February 22, 2022)  Averix Bio today announces its submission of a  Drug Master File (DMF) to the US Food & Drug Administration (FDA) for cannabidiol (CBD) isolate. Unlike most manufacturers, Averix ingredients are not synthetic but instead made from phytocannabinoid industrial hemp. The submission (DMF 036798) signifies Averix Bio’s

      Source: FDA   There are two different ways to produce cannabis compounds – either through the traditional grow method which yields phytocannabinoids or from the lab which yields synthetic cannabinoids. The exception to the former is of course the recent production of cannabinoids from microorganisms like yeast; here, we will consider these

ALTEROLA BIOTECH SELECTS AVERIX BIO TO SUPPLY API PHYTOCANNABINOID CBD ISOLATE BIRKENHEAD, UK (Dec. 24, 2021) — Alterola Biotech Inc. (OTC PINK:ABTI) today announces the execution of a Memorandum of Understanding (MoU) to enter into a Good Manufacturing Practice (GMP) supply agreement with Averix Bio LLC (“Averix Bio”), a North Carolina-registered company whose registered office is

Averix Bio, a Botanical-based Cannabinoid Supplier, Achieves cGMP 21 CFR Part 210 and Part 211 and ICH Q7 Compliance Pharmaceutical, nutraceutical and cosmetic companies can now secure API Phytocannabinoid CBD isolate for preclinical, clinical and manufacturing   Wilson, N.C., (Oct. 12, 2021) — Averix Bio is proud to announce that it has successfully completed an independent audit

Avient Biosciences Adopts New Name to Signal Move to 21 CFR Part 210 and Part 211 Compliance North Carolina-based company producing cannabinoid ingredients that meet pharmaceutical-grade cGMP criteria Wilson, N.C., (July 30, 2021) — The largest industrial hemp research, extraction and production company in the eastern U.S. has adopted a new name, Averix Bio, to signal